麻豆传媒

Debu Tripathy, MD walks us through some of the key findings from this year's meeting

Updated data solidify ADC as standard-of-care second-line therapy, says Sara Hurvitz, MD

Fran莽ois-Cl茅ment Bidard, MD, PhD, discusses results from two studies

Trastuzumab deruxtecan prolonged PFS and boosted responses in all patient subgroups

Updated results show 9-month survival benefit in those with active or untreated brain metastases

Amy Tiersten, MD, discusses new data from the PHOEBE trial

Analysis highlights need for further research, says Megan Kruse, MD

Halle Moore, MD discusses the results of the IBIS-II trial

It's a niche where many new drugs are coming, says Debu Tripathy

Study author Rashmi Murthy and Amy Tiersten discuss the HER2CLIMB trial